Myomo's Strategic Turnaround: A Buy Rating With Revenue Growth and Operational Scaling on the Horizon
Myomo Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Myomo, Maintains $6.5 Price Target
Myomo Inc.: Strong Growth and Regulatory Tailwinds Support Buy Rating
HC Wainwright & Co. Initiates Coverage On Myomo With Buy Rating, Announces Price Target of $6.5
Myomo Analyst Ratings
Maxim Group Keeps Their Buy Rating on Myomo (MYO)
Ascendiant Sticks to Its Buy Rating for Myomo (MYO)
Myomo (MYO) Receives a Buy From Maxim Group
Maxim Group Initiates Coverage On Myomo With Buy Rating, Announces Price Target of $2
No Data